Mirum Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MIRM and other ETFs, options, and stocks.

About MIRM

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. 

CEO
Christopher Peetz
CEOChristopher Peetz
Employees
372
Employees372
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
2018
Founded2018
Employees
372
Employees372

MIRM Key Statistics

Market cap
5.22B
Market cap5.22B
Price-Earnings ratio
-5.71
Price-Earnings ratio-5.71
Dividend yield
—
Dividend yield—
Average volume
727.63K
Average volume727.63K
High today
$83.00
High today$83.00
Low today
$80.24
Low today$80.24
Open price
$82.39
Open price$82.39
Volume
787.96K
Volume787.96K
52 Week high
$130.00
52 Week high$130.00
52 Week low
$63.23
52 Week low$63.23

Stock Snapshot

As of today, Mirum Pharmaceuticals(MIRM) shares are valued at $80.39. The company's market cap stands at 5.22B, with a P/E ratio of -5.71.

During the trading session on 2026-10-23, Mirum Pharmaceuticals(MIRM) shares reached a daily high of $83.00 and a low of $80.24. At a current price of $80.39, the stock is +0.2% higher than the low and still -3.1% under the high.

Trading volume for Mirum Pharmaceuticals(MIRM) stock has reached 787.96K, versus its average volume of 727.63K.

Over the past 52 weeks, Mirum Pharmaceuticals(MIRM) stock has traded between a high of $130.00 and a low of $63.23.

Over the past 52 weeks, Mirum Pharmaceuticals(MIRM) stock has traded between a high of $130.00 and a low of $63.23.

MIRM News

Simply Wall St 8h
How Investors May Respond To Mirum Pharmaceuticals Phase 3 Trial Success

Mirum Pharmaceuticals reported positive topline Phase 3 EXPAND data for LIVMARLI in ultra rare cholestatic liver diseases, with the trial meeting its primary it...

TipRanks 2d
Mirum Pharmaceuticals’ brelovitug receives FDA orphan designation

Mirum Pharmaceuticals (MIRM)’ brelovitug received FDA orphan designation for the treatment of active hepatitis delta virus infection, according to a post to the...

Analyst ratings

100%

of 14 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own MIRM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.